Biotechs' financing deals help with development costs

05/8/2006 | American City Business Journals

Biotechnology companies already burdened with funding treatments nearing market approval are entering into agreements with private-equity firms to create separate entities to help shoulder the risk and cost associated with developing promising early-stage drugs. This financing mechanism fell out of favor amid some scandals involving off-balance sheet arrangements, but the new deals are transparent and the entities' financial dealings are covered in the parent company's statements.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC